Velarion · Company Intelligence
CompBrief
Fiscal year 2025

Richard Adcock — FY2025 total compensation $12,716,953

Richard Adcock is President and CEO of ImmunityBio, Inc. (IBRX). The company reported total compensation of $12,716,953 for fiscal year 2025.

01

Fiscal year 2025 compensation

Salary$831,667
Bonus$141,684
Stock awards$2,787,828
Option awards$8,353,406
Non-equity incentive plan$485,166
Pension and non-qualified deferred compensation$0
All other compensation$117,202
Total$12,716,953

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.

Cited to the compensation disclosure ImmunityBio, Inc. filed April 30, 2026, accession 0001326110-26-000049.

03

Peer context

Peer-group chief executive median$13,462,970
Difference from that median$-746,016
Percentile within the disclosed peer group33rd
Peers with a disclosed figure6

Medians and percentiles are computed across the peer group ImmunityBio, Inc. discloses in its own compensation disclosure.

04

The other named executive officers of ImmunityBio, Inc.

Named executive officerRoleFY2025 total
Richard Adcock this pagePresident and CEO$12,716,953
Patrick Soon-ShiongFounder, Executive Chairman of the Board and Global Chief Scientific and Medical Officer$12,293,255
David SachsCFO$4,244,543
Regan LauerChief Accounting Officer$745,313

The company's named executive officers for fiscal year 2025, and what it reported for each. See the full ImmunityBio, Inc. compensation brief.

05

The company page

Richard Adcock's compensation sits inside ImmunityBio, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.

The ImmunityBio, Inc. (IBRX) compensation brief